An analysis of the development achievements in pediatric drugs in China driven by policyLIANG Yu-guang, DING Qian, WANG Qian, ZHANG Meng, GUO Chun-yan, GUO Peng1345-1350
Strategies for optimizing models to enhance production efficiency in the blood products industryLI Ze-yu, XU Yang, LIU Yun-peng, LU Kui-lin, YU Ding, YANG Yue1351-1358
A comparative analysis of the evolution of drug regulatory science policies in China and the United States based on text visualizationJIAO Zu-fang, LI Jun, LAN Ya-fei, MAO Ning-ying1359-1367
Characteristics and insights of the European Medicines Agency guideline developmentSUN Tan-lin, XU Zhen-yu1368-1372
Trends and innovation analysis of new drug approvals in China and the United States from 2018 to 2023ZHANG Dong, REN Feng, NIU Han-dong, CHEN Ai-ping, ZHANG Jing-chen1373-1383
The research and application progress of large language models in drug developmentGUO Jin-long, XU Xin, LIU Li-li, MAO Yan-yan1384-1390
Study on the quality of echinocandin antibiotics-ⅠLI Bin, TIAN Ye, DI Xin, LI Jin, NING Bao-ming1391-1395
Chinese expert consensus on clinical application of levofolinic acid in the sensitization of chemotherapy for gastrointestinal tumorsLIU Bo, ZHANG Hong-yan1396-1401
Envafolimab combined with capecitabine in TERT-mutant advanced biliary tract cancer:a case reportWANG Kai-yu, GUO Tian-yu, ZHANG Lei, ZHAO Hao-yu, WEI Ze-yuan, LIU Ye-fu, MA Zuo-hong1402-1405
Progress in the study of chemical composition and pharmacological effects of Imperatae rhizoma and its quality marker predictionLI Shuai-yin, YANG Ping, XI Hui-rong, CHEN Ting, LI Xi-xiang1406-1416